Business Context and Reporting Period
This Form 8-K, dated October 17, 2022, reports on LMF Acquisition Opportunities, Inc. ("LMF"), a Delaware corporation and special purpose acquisition company (SPAC). LMF is in the process of a business combination with SeaStar Medical, Inc. Upon closing, LMF will change its name to SeaStar Medical Holdings Corporation. The filing details a material definitive agreement entered into on October 17, 2022, involving a Prepaid Forward Transaction.
Key Financial Metrics and Transaction Terms
The filing does not provide standard financial statements (revenue, profit, cash flow) for the reporting period. Instead, it outlines specific financial terms of the Prepaid Forward Agreement:
- Maximum Share Volume: The Seller (Vellar Opportunity Fund SPV LLC - Series 4) may purchase up to 1,500,000 "Recycled Shares" (redeemed shares) in the open market.
- Ownership Cap: The Seller cannot beneficially own more than 9.9% of issued and outstanding shares following the business combination.
- Prepayment Amount: Upon closing, the Seller receives a cash amount from LMF's trust account equal to the number of Recycled Shares multiplied by the Per-Share Redemption Price.
- Share Consideration: An additional payment is made for 100,000 "Additional Shares" purchased by the Seller prior to closing.
- Reset Price: Initially set at $10.00 per share post-closing, subject to monthly adjustments based on the lowest of the current price, $10.00, or the 10-day VWAP, with a floor of $5.00.
- Maturity Consideration: At maturity, the Counterparty must pay the Seller $2.50 per share for the remaining shares in the transaction.
- Break-Up Fee: If the transaction is terminated by the Counterparty or SeaStar Medical Holdings after closing, a fee of $1,000,000 plus actual out-of-pocket expenses is payable to the Seller.
Material Changes and Transaction Mechanics
The primary material change is the execution of the Prepaid Forward Agreement to facilitate the business combination. Key mechanics include:
- Recycling Redeemed Shares: The agreement allows the Seller to purchase shares from holders who elected to redeem their shares, effectively recycling them into the transaction.
- Termination Triggers: The agreement terminates if the business combination is not consummated by October 29, 2022 (subject to extension), if the Merger Agreement is terminated, or if the shares are delisted.
- Maturity Date: The transaction matures on the third anniversary of the closing or earlier if a "VWAP Trigger Event" occurs (VWAP below $3.00 for 20 of 30 consecutive trading days).
- Voting Rights: The Seller does not possess redemption rights and is not eligible to vote the shares in favor of the business combination.
Guidance, Risks, and Contingencies
The filing contains extensive forward-looking statements and risk factors regarding the proposed business combination:
- Completion Risk: There is a risk the business combination may not be completed in a timely manner or at all, potentially affecting security prices.
- Regulatory and Approval Risks: Risks include failure to satisfy conditions for consummation, such as stockholder approval and maintaining the minimum trust account amount.
- Operational Risks: SeaStar Medical faces risks related to product development, commercialization, regulatory approvals, and the ability to achieve or sustain profitability.
- Capital Needs: SeaStar Medical may need to raise additional capital, which may not be available on acceptable terms.
- Market Risks: Risks include the inability to maintain Nasdaq listing, competition, and potential product liability lawsuits.
Investor Verification Checklist
- Verify the status of the Merger Agreement and the October 29, 2022, closing deadline.
- Review the Form S-4 Registration Statement for detailed financial projections and risk factors.
- Confirm the current redemption status and the impact of the Prepaid Forward Agreement on the trust account balance.
- Monitor the stock price relative to the $3.00 VWAP Trigger Event and the $5.00 Reset Price floor.
- Assess SeaStar Medical's progress on regulatory approvals and product commercialization.